Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00144638 |
| Other study ID # |
DPSG1 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
September 1, 2005 |
| Last updated |
September 1, 2005 |
| Start date |
January 2002 |
| Est. completion date |
January 2003 |
Study information
| Verified date |
February 2005 |
| Source |
Danish Procalcitonin Study Group |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Denmark: National Board of Health |
| Study type |
Observational
|
Clinical Trial Summary
Procalcitonin, a marker of infection has often been compared to clinical pictures as for
instance "clinical sepsis". This has given som problems in the interpretation of these
studies, because of the lack of good Gold Standards for "clinical sepsis. We have decided to
investigate the development from day to day of Procalcitonin in the blood of intensive care
patients, compared to the mortality.
Hypothesis: Procalcitonin increase after reaching a certain level predicts mortality in the
Intensive Care Unit.
Description:
Sepsis is a major cause of mortality in the Intensive Care Unit (ICU). Efforts have been
made to reduce the time needed to diagnose sepsis in order to reduce mortality from
sepsis-related multi-organ dysfunction .
Markers of inflammation such as C-reactive protein (CRP) and White Blood Cell count (WBC)
have proved far from ideal in identifying critically ill patients who need antimicrobial
therapy, because the sensitivity and specificity for bacterial infection is low.
Procalcitonin (PCT) is a 13 kDa 116 amino acid polypeptide, initially described as a
prohormone of Calcitonin, a hormone of the calcium metabolism produced in the medullary
C-cells of the Thyroid gland5-7. However, recent studies demonstrated that the variant PCT
associated with infection can be produced by other tissues.
As kinetic studies on baboons and humans have shown a rapid release within 2-4 hours after
injection of bacteria or bacterial toxins, PCT is a substance which is released more rapidly
than CRP. The plasma half-life of PCT is close to 24 hours. Measurements of PCT in healthy
individuals have shown very low serum levels (<0.05 ng/ml).
In 1993, Assicot et al. reported that elevated levels of serum procalcitonin were closely
related to the onset of bacterial infection and seemingly correlated to severity of
infection.
Several clinical studies have detected a high PCT level in patients with evidence of
systemic bacterial infection, while relatively low PCT levels, on the other hand, occur in
patients with only local bacterial infection or viral infection.
Other studies have shown low to only moderately elevated PCT in uninfected patients after
major surgery, trauma and after myocardial infarction.
A reduced usage of antimicrobial therapy has been demonstrated when treatment was guided by
PCT in patients with suspected lower respiratory tract infection, who were admitted to a
medical emergency department. Only few studies, however, have investigated the PCT
day-to-day changes for several days in respect of the clinical outcome in a population at
risk of contracting serious infections.
The aim of the present study was to assess the ability of PCT-, CRP- and leucocyte
measurements in early identification of critically ill patients, who are at high risk of
mortality. The study was a one-year study.
Methods Patients From January 2 through December 2002, we conducted an observational study
including all patients (except livertransplanted patients) admitted to the
multi-disciplinary intensive care unit 4131 at Rigshospitalet, Copenhagen University
Hospital, a secondary and tertiary reference hospital. Patients were included on admittance
to the ICU. In cases of re-admittance, only measurements from the first admittance were
included in the study.
When sepsis was suspected, we performed culture samples from all suspected sites before
antibiotic therapy was initiated. Surveillance culture samples were performed twice a week
from all patients, including blood cultures from indwelling catheters.
Data of co-morbidity and mortality were registered real-time and were verified via the
central hospital register for Rigshospitalet, Copenhagen University Hospital.
In all analyses, mortality was defined as all-cause mortality. The primary endpoint was
90-day survival; secondary endpoints were survival while admitted to the ICU and 30-day
survival.
Blood samples Blood samples for PCT measurements were collected by the nursing staff in the
ICU on a daily basis between 6.00 a.m. and 7.30 a.m. in accordance with the assumed half
life of PCT. PCT analyses were performed by laboratory technicians at the Department of
Clinical Microbiology, using an immunoluminometric assay (Lumitest-PCT, B.R.A.H.M.S.
Diagnostica, Berlin, Germany). The threshold of detection was 0.1 ng/ml serum, according to
the manufacturer.
Blood samples were collected as a routine test in accordance with the ethical procedures of
the hospital.
All blood samples were stored at 4o Celsius, and were analysed within maximally 72 hours. As
a control of the PCT analysis and storage, we made double determinations. Ten blood samples
were analysed single-blinded three times daily at a standardised time for three days.
PCT-day-to-day change analysis Standard empiric antimicrobial treatment of sepsis in this
ICU includes: Meropenem and Ciprofloxacin, when relevant supplemented with: Metronidazole,
Vancomycin, Linezolid and occasionally other antibiotics according to clinical findings,
patient tolerance, suspected site of infection and bacterial cultures from foci and from
surveillance cultures combined with susceptibility patterns. Treatment of invasive fungal
infection included Caspofungin, Liposomal Amphotericin B or Voriconazole, or combination
therapy with these according to Candida species identification and susceptibility pattern
from Minimal Inhibitory Concentration (MIC) in surveillance cultures.
